Pardes Biosciences to suspend COVID-19 drug development after mid-stage trial fails
03/04/2023 13:12
April 3 (Reuters) - Pardes Biosciences Inc PRDS.O said on Monday it will suspend further clinical development of its experimental drug pomotrelvir, after it did not meet the main goal of a mid-stage trial for treating COVID-19. (Reporting by Raghav Mahobe in Bengaluru; Editing by Krishna Chandra Eluri) ((Raghav.Mahobe@thomsonreuters.com;))
Recent news on Pardes Biosciences
See all newsBrief: Pardes Biosciences Inc - Total Cash Amount That Medipacific Sub, Inc. Will Pay Pursuant To Terms Of Offer And Merger Agreement Is $2.13 Per Share
U.S. STOCKS ON THE MOVE-Argenx, ViewRay, Ford
Pardes Biosciences up on buyout deal with MediPacific
U.S. STOCKS ON THE MOVE-Activision Blizzard, Tesla, Paramount Global
Pardes Biosciences gains on buyout deal with MediPacific